TCGA-CF-A3MH-01A-11R-A20F-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 13.07490145
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_LATE+0.370
- P53_PATHWAY+0.320
- ESTROGEN_RESPONSE_EARLY+0.310
- KRAS_SIGNALING_DN+0.250
- HEDGEHOG_SIGNALING+0.190
- COAGULATION+0.160
- APICAL_SURFACE+0.150
- HYPOXIA+0.150
- GLYCOLYSIS+0.120
- NOTCH_SIGNALING+0.120
Top 10 suppressed
- E2F_TARGETS-0.450
- INTERFERON_GAMMA_RESPONSE-0.440
- G2M_CHECKPOINT-0.420
- INTERFERON_ALPHA_RESPONSE-0.410
- UNFOLDED_PROTEIN_RESPONSE-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.360
- ALLOGRAFT_REJECTION-0.340
- PROTEIN_SECRETION-0.340
- MYC_TARGETS_V1-0.310
- MITOTIC_SPINDLE-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2208949 | — | — | 0.834 |
| 2 | aMVAC.P_003_TURBT_S220 | — | — | 0.832 |
| 3 | MNG1264 | — | — | 0.823 |
| 4 | TCGA-E2-A14U-01A-11R-A22K-07 | — | A | 0.805 |
| 5 | s0112300 | — | — | 0.798 |
| 6 | TCGA-98-A53J-01A-11R-A26W-07 | — | cohortSQ2 | 0.796 |
| 7 | TCGA-GM-A3XG-01A-31R-A24H-07 | — | A | 0.788 |
| 8 | TCGA-AC-A3TN-01A-11R-A22K-07 | — | B | 0.778 |
| 9 | 3e1c728a-cf38-4ca8-9d87-0bbf098567a6 | — | — | 0.772 |
| 10 | 299f36bd-d9fd-41f5-8a29-3382e147a14f | — | — | 0.764 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_LATE | 0.370 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.320 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.310 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.120 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.120 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| PEROXISOME | 0.080 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.070 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.060 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.050 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.050 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.030 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.030 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.020 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.010 | Remibrutinib | — uncovered |